Gene therapy for Leber congenital amaurosis (LCA), an inherited disorder that causes loss of night- and day-vision starting in childhood, improved patients’ eyesight within weeks of treatment in a…
AIDS patients at increased risk of developing intermediate-stage AMD
Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV, according to resul…
Gene Tx: Temporary Boost in Congenital Blindness (CME/CE)
(MedPage Today) — Leber’s amaurosis responds to high-dose gene therapy, but not permanently.
Premium Intraocular Lenses Growing in Popularity
More patients with presbyopia might benefit from intraocular lenses, say experts, who report that the lenses might even be useful for patients younger than cataract age. Medscape Medical News
Retinal Gene Therapy: Long-term Results Less Than Expected
Gene therapy for RPE65-associated Leber’s congenital amaurosis enabled people to see, but the benefit diminished as photoreceptors continued to degrade in patients treated in two trials. Medscape Medical News
Uncategorized
Are you in an Alternative Payment Model? Why it matters
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.The recently enacted Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) repealed the long-criticized Sustainable Growth Rate but added new elements to Medicare’s methods for determining physician payments (see our previous post on new payment options). Starting in 2019, a physician participating in certain “Alternative Payment Models,” or APMs, may receive a 5% bonus (2019-2024) or a (Read more...)